JPH10513470A - Ｉｌ−６の効果を阻害する方法 - Google Patents

Ｉｌ−６の効果を阻害する方法

Info

Publication number
JPH10513470A
JPH10513470A JP8524393A JP52439396A JPH10513470A JP H10513470 A JPH10513470 A JP H10513470A JP 8524393 A JP8524393 A JP 8524393A JP 52439396 A JP52439396 A JP 52439396A JP H10513470 A JPH10513470 A JP H10513470A
Authority
JP
Japan
Prior art keywords
cells
raloxifene
inhibiting
formula
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8524393A
Other languages
English (en)
Japanese (ja)
Inventor
グレイスブルック，アンドリュー・エル
ザッカーマン，スティーブン・エイチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPH10513470A publication Critical patent/JPH10513470A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP8524393A 1995-02-06 1996-02-05 Ｉｌ−６の効果を阻害する方法 Pending JPH10513470A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06
US08/384,730 1995-02-06
PCT/US1996/001621 WO1996024356A1 (en) 1995-02-06 1996-02-05 Methods of inhibiting effects of il-6

Publications (1)

Publication Number Publication Date
JPH10513470A true JPH10513470A (ja) 1998-12-22

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8524393A Pending JPH10513470A (ja) 1995-02-06 1996-02-05 Ｉｌ−６の効果を阻害する方法

Country Status (14)

Country Link
EP (1) EP0724879A2 (2)
JP (1) JPH10513470A (2)
KR (1) KR19980701933A (2)
CN (1) CN1173819A (2)
AU (1) AU708374B2 (2)
CA (1) CA2212232A1 (2)
CZ (1) CZ246597A3 (2)
FI (1) FI973235A0 (2)
HU (1) HUP9801829A3 (2)
IL (1) IL117036A0 (2)
NO (1) NO973609L (2)
WO (1) WO1996024356A1 (2)
YU (1) YU6996A (2)
ZA (1) ZA96897B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
KR20020009383A (ko) 1998-04-01 2002-02-01 우에노 도시오 축합 티오펜 유도체 및 이의 유도체를 유효 성분으로 하는약제
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
ES2207982T3 (es) * 1998-12-30 2004-06-01 Signal Pharmaceuticals, Inc. Compuestos y metodos para la modulacion de receptores estrogenicos.
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2005125043A (ru) * 2003-01-06 2006-01-27 Уайт (Us) Применение модуляторов альфа-рецепторов эстрогена для лечения рассеянного склероза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (2) * 1993-07-22 1997-04-21 Lilly Co Eli
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
EP0724879A2 (en) 1996-08-07
FI973235A7 (fi) 1997-08-05
KR19980701933A (ko) 1998-06-25
NO973609L (no) 1997-09-11
ZA96897B (en) 1997-08-05
WO1996024356A1 (en) 1996-08-15
NO973609D0 (no) 1997-08-05
FI973235L (fi) 1997-08-05
EP0724879A3 (2) 1996-09-11
MX9705940A (es) 1997-10-31
HUP9801829A3 (en) 1999-10-28
IL117036A0 (en) 1996-06-18
CA2212232A1 (en) 1996-08-15
AU4916396A (en) 1996-08-27
AU708374B2 (en) 1999-08-05
HUP9801829A2 (hu) 1999-05-28
FI973235A0 (fi) 1997-08-05
CN1173819A (zh) 1998-02-18
CZ246597A3 (cs) 1998-06-17
YU6996A (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
KR0161300B1 (ko) 뼈 손실 예방에 유용한 벤조티오펜
US5496828A (en) Methods of inhibiting ulcerative mucositis
US5494920A (en) Methods of inhibiting viral replication
EP0681836A1 (en) Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
HUT71234A (en) Pharmaceutical compositions inhibiting smooth muscle cell proliferation and restinosis containing 2-phenyl-3-aroyl-benzotiophene- and 2-phenyl-3-aroyl-naphtalene derivatives and process for their preparation
JPH07215859A (ja) 月経時の症状の治療法およびそれに用いる組成物
US5521198A (en) Methods of inhibiting autoimmune diseases
AU677701B2 (en) Methods for inhibiting angiogenisis and angiogenic diseases
AU692490B2 (en) Methods of inhibiting dysfunctional uterine bleeding
JPH10505823A (ja) 脱髄性及び髄鞘形成障害性疾患を抑制する方法
AU701701B2 (en) Methods of inhibiting breast disorders
JPH07215865A (ja) 閉経後女性の性欲を増進するための方法
JPH07242546A (ja) ミエロペルオキシダーゼ活性の阻害に適した医薬組成物
HUT71337A (en) Pharmaceutical compositions for inhibiting turner's syndrome containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
AU708374B2 (en) Methods of inhibiting effects of IL-6
JPH11513665A (ja) プラスミノーゲンアクチベーターインヒビター１の阻害方法
US5672610A (en) Methods of increasing macrophage function
MXPA97005940A (en) . methods and compositions to inhibit the effects of interleucin
KR20010052892A (ko) 아세틸콜린 수치를 상승시키는 방법
US5985932A (en) Inhibition of autoimmune diseases
JPH08231395A (ja) 子宮類線維腫疾患抑制用製剤